San Francisco, November 10, 2023(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will present Phase 2 clinical data evaluating the potential of VIR-3434 and VIR-2218 in chronic hepatitis B. Clinical Impact on Patients with Chronic Hepatitis D (CHB) and Chronic Hepatitis D (CHD) Attend American Association for the Study of Liver Diseases (AASLD) Liver Meeting®, taking place November 10-14, 2023 in Boston, Massachusetts. These include an updated poster presentation and an updated oral presentation.
the recent report
-
title: VIR-2218 and VIR-3434 with or without peginterferon Alfa-2A in the treatment of chronic HBV infection: end-of-treatment (EOT) results after 24 weeks of treatment (March Study Part B) (Abstract #48500)
Meeting: Latest Poster Session
date: Monday, November 13
time: 1:00 p.m. Eastern Time
host: Edward Gane, MD, professor of medicine at the University of Auckland, New Zealand, chief hepatologist and transplant physician at Auckland City Hospital and deputy director of the New Zealand Liver Transplantation Department
-
title: Monoclonal Antibody VIR-3434 and siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
Meeting: Oral, evening parallel sessions
date: Monday, November 13
time: 3:00 p.m. Eastern Time
host: Tarik Asselah, MD, PhD, Professor of Hepatology, Hospital Clichy-Beaujon, APHP and University of Paris, France, Director of Viral Hepatitis, INSERM UMR1149, France
A summary of AASLD’s latest presentations can be accessed under Events and Presentations in the Investors section of the Vir website.
Vir will host an investor conference call on November 13 at 1:30 pm PT/4:30 pm ET to discuss Phase 2 CHD and CHB AASLD data. The webcast will be hosted at https://investors.vir.bio and will be archived at www.vir.bio for 30 days.
About chronic hepatitis B
Chronic hepatitis B (CHB) infection remains an urgent global public health challenge with high morbidity and mortality. Approximately 300 million people worldwide suffer from chronic hepatitis B, and approximately 900,000 people die from related complications every year. These patients are significantly underserved by existing therapies with low functional cure rates, lifelong daily treatment, and/or poor tolerability. Vir is committed to achieving functional cures for the millions of people living with chronic hepatitis B around the world through its broad and differentiated product portfolio.
About chronic hepatitis D
Chronic hepatitis D (CHD) infection is concurrent or superinfected with chronic hepatitis B. An estimated 12 million people worldwide are infected with CHD, accounting for approximately 5% of those infected with CHB. CHB-CHD co-infection is considered the most severe form of chronic viral hepatitis because it leads to more rapid progression to hepatocellular carcinoma and liver-related death.
About VIR-3434
VIR-3434 is an investigational, subcutaneously administered antibody designed to block the entry of hepatitis B and hepatitis D viruses into liver cells and reduce levels of virions and subviral particles in the blood. VIR-3434 combines Xencor’s Xtend™ and other Fc technologies and is engineered as a T-cell vaccine against hepatitis B virus and hepatitis delta virus with an extended half-life. VIR-3434 was identified using Vir’s proprietary monoclonal antibody discovery platform.
About VIR-2218
VIR-2218 is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate immune responses and have direct antiviral activity against hepatitis B virus and hepatitis delta virus . It is the first siRNA in the clinic to employ enhanced stability chemical enhancement (ESC+) technology to enhance stability and minimize off-target activity, which may result in an increased therapeutic index. VIR-2218 is the first asset from the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious diseases. Vir has assembled two technology platforms designed to stimulate and enhance the immune system by leveraging key observations of natural immune processes. Its current clinical development pipeline includes product candidates targeting hepatitis B, hepatitis D virus and human immunodeficiency virus. Vir has multiple preclinical drug candidates in development, including candidates targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir frequently posts information on its website that may be important to investors.
forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “goal,” “expect,” “anticipate,” “hopefully” and similar expressions (as well as references to future events, conditions or circumstances or other words or expressions) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategies and plans, the potential clinical effects of VIR-3434 and VIR-2218, the potential benefits, safety and efficacy of VIR-3434 and VIR-2218 , data from Vir’s multiple ongoing trials evaluating VIR-3434 and VIR-2218, Vir’s plans and expectations for its HBV and HDV product portfolios, and the risks and uncertainties associated with drug development and commercialization. Many factors could cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or data readouts; the occurrence of adverse safety events; unexpected costs, delays or other Risk of unexpected obstacles; difficulties in collaborating with other companies; success by Vir’s competitors in developing and/or commercializing alternative product candidates; changes in anticipated or existing competition; geopolitical changes (including the war in Ukraine) due to the COVID-19 pandemic or other external factors, delays or interruptions in Vir’s business or clinical trials; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a few research and development projects lead to commercialization of products. Results from early-stage clinical trials may not be representative of the full range of results or results from later-stage or larger clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented. Additional factors that could cause actual results to differ from those expressed or implied by the forward-looking statements in this press release are discussed in Vir’s filings with the Securities and Exchange Commission, including in the section titled “Risk Factors” therein. Except as required by law, Vir disclaims any obligation to update any forward-looking statements contained herein to reflect changes in expectations, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231106658171/en/
Contact information
half
Carly Scaduto
Senior Director of Media Relations
cscaduto@vir.bio
+1-314-368-5189
investor
Sasha Damuni Ellis
Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio